ANTIHYPERTENSIVE AND LIPID LOWERING TO PREVENT HEART ATTACK TRIAL (ALLHAT)

抗高血压和降脂预防心脏病试验 (ALLHAT)

• 批准号: 6281657
• 负责人: CARLOS A HERRERA
• 金额: $ 1.36万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6281657
• 关键词: ACE inhibitors; alpha adrenergic agent; antihypercholesterolemic agent; antihypertensive agents; calcium channel blockers; cardiovascular disorder epidemiology; cardiovascular disorder prevention; chemoprevention; clinical research; clinical trials; coronary disorder; disease /disorder proneness /risk; diuretics; heart disorder chemotherapy; human subject; human therapy evaluation; myocardial infarction

This is a clinical trial of antihypertensive pharmacologic treatment and, in a specific subset, cholesterol-lowering, in high-risk hypertensive patients. The purpose is to determine whether the incidence of coronary heart disease and myocardial infarction differs between diuretic treatment and three alternative antihypertensive pharmacologic treatments - a calcium antagonist, an ACE inhibitor, and an alpha adrenergic blocker. To date we have enrolled 53 patients. Enrollment is closed and we are in the follow-up period. Future plans are to monitor for cardiovascular events and maintain enrollees in the protocol.

这是降压药物治疗的临床试验， 在高风险高血压的特定子集中，降低胆固醇 患者。 目的是确定冠状动脉的发生 心脏病和心肌梗死在利尿治疗之间有所不同 和三种替代性降压药物治疗 - a 钙拮抗剂，ACE抑制剂和α肾上腺素能阻断剂。 迄今为止，我们已经招募了53名患者。 入学人数已关闭，我们正在 后续期。 未来的计划是监测心血管 事件并维护协议中的参与者。